手术前感应化疗对非小细胞性肺癌有效
WESTPORT, Mar 20 (Reuters Health) - Among patients with early-stage non-small cell lung cancer who received preoperative induction chemotherapy of paclitaxel and carboplatin, 85% survived for one year, researchers report in the March issue of The Journal of Thoracic and Cardiovascular Surgery.
Dr. Katherine M. W. Pisters of the University of Texas M.D. Anderson Cancer Center in Houston and colleagues administered two cycles of preoperative paclitaxel and carboplatin to 94 patients with early-stage non-small cell lung carcinoma. Patients who were underwent complete resection were scheduled to receive three additional cycles postoperatively.
Ninety-six percent of the patients received the planned preoperative chemotherapy, but only 45% of those eligible received the postoperative dose.
The investigators observed a major objective response in 53 (56%) of the patients after induction chemotherapy. Eighty-eight of the patients underwent surgical exploration and 81 had a complete resection performed.
Six of the patients experienced pathologic complete response. Dr. Pisters‘ group reports that there was no unexpected chemotherapy or surgical morbidity. The estimated 1-year survival rate is 85%, and the 2-year survival 56%.
"Induction chemotherapy with paclitaxel and carboplatin is feasible and produces a high response rate with acceptable morbidity and mortality rates in early-stage non-small cell lung carcinoma," Dr. Pisters and colleagues conclude.
The authors that a trial comparing three cycles of the chemotherapy and surgery with surgery alone in early-stage non-small cell lung carcinoma patients is currently underway.
In a comment to Reuters Health, Dr. Pisters said the therapy is not recommended for patients with "poor pulmonary function, inadequate liver or kidney function, significant cardiac disease, or active infection." She added, "These are general criteria for selecting patients who are appropriate to undergo chemotherapy and surgery.", 百拇医药
Dr. Katherine M. W. Pisters of the University of Texas M.D. Anderson Cancer Center in Houston and colleagues administered two cycles of preoperative paclitaxel and carboplatin to 94 patients with early-stage non-small cell lung carcinoma. Patients who were underwent complete resection were scheduled to receive three additional cycles postoperatively.
Ninety-six percent of the patients received the planned preoperative chemotherapy, but only 45% of those eligible received the postoperative dose.
The investigators observed a major objective response in 53 (56%) of the patients after induction chemotherapy. Eighty-eight of the patients underwent surgical exploration and 81 had a complete resection performed.
Six of the patients experienced pathologic complete response. Dr. Pisters‘ group reports that there was no unexpected chemotherapy or surgical morbidity. The estimated 1-year survival rate is 85%, and the 2-year survival 56%.
"Induction chemotherapy with paclitaxel and carboplatin is feasible and produces a high response rate with acceptable morbidity and mortality rates in early-stage non-small cell lung carcinoma," Dr. Pisters and colleagues conclude.
The authors that a trial comparing three cycles of the chemotherapy and surgery with surgery alone in early-stage non-small cell lung carcinoma patients is currently underway.
In a comment to Reuters Health, Dr. Pisters said the therapy is not recommended for patients with "poor pulmonary function, inadequate liver or kidney function, significant cardiac disease, or active infection." She added, "These are general criteria for selecting patients who are appropriate to undergo chemotherapy and surgery.", 百拇医药